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22 
One Sentence Summary:  23 
A combination of virally-delivered SOD2 and CTGF gene therapies can protect non-cancerous 24 
tissues from the long-term side effects of radiotherapy  25 
 26 
 27 
Abstract: Improvements in cancer survival mean that long-term toxicities are being increasingly 28 
recognised that contribute to the morbidity of cancer survivorship. Late adverse effects (LAEs) 29 
in normal tissues after radiotherapy (RT) are characterized by vascular dysfunction and fibrosis 30 
leading to volume loss and tissue contracture. For example, irradiation of free flaps used for 31 
immediate breast reconstruction after mastectomy results in LAEs that distort the reconstructed 32 
breast, necessitating salvage reconstruction long after cancer treatment is complete. We 33 
evaluated the efficacy of lentiviral superoxide dismutase 2 (LVSOD2) and connective tissue 34 
growth factor (CTGF) shRNA in reducing the severity of LAEs using a novel animal model of 35 
free flap LAEs. Vectors were delivered by intra-arterial injection, ex vivo, to target the vascular 36 
compartment. LVSOD2 and LVshCTGF monotherapy prior to irradiation resulted in significant 37 
preservation of flap volume or reduction in skin contracture, respectively. Flaps transduced with 38 
combination therapy experienced significant improvements in both volume loss and skin 39 
contracture. Both therapies significantly reduced the fibrotic burden after irradiation. LAEs were 40 
associated with impaired vascular perfusion, loss of endothelial permeability and stromal 41 
hypoxia that were further reversed in the described treatment model. Using a model of tumour 42 
recurrence within transduced flaps we showed that SOD2 over-expression in normal tissues did 43 
not compromise the cytotoxic efficacy of RT against tumour cells but instead, paradoxically, 44 
appeared to enhance it. LVSOD2 and LVshCTGF combination therapy by targeted, intra-45 
vascular delivery reduced LAE severities in normal tissues without compromising the efficacy of 46 
RT and warrants translational evaluation as a free flap-targeted gene therapy.  47 
 48 
49 
Introduction 50 
Ever improving cancer survival means that the long-term toxicities of cancer treatments 51 
that contribute to the morbidity of cancer survivorship are being increasingly recognized. For 52 
example, for women diagnosed with small screen-detected breast cancers, it is the late 53 
complications of radiotherapy, rather than the risk of loco-regional recurrence(1, 2), that are the 54 
dominant hazard. Late adverse effects (LAEs) in the breast include breast shrinkage, hardening, 55 
discomfort and skin changes. These changes (3-7) also occur in breasts that have been 56 
reconstructed with free flaps after mastectomy and augur a poorer long-term aesthetic outcome. 57 
Re-operation rates for flaps affected in this manner are significant and, in some cases, salvage 58 
reconstruction with a second free flap remains the only option. Such late adverse effects (LAEs) 59 
incur significant physical and psychological morbidity in cancer survivorship. Therefore, if 60 
adjuvant RT may be required, and when the surgical defect allows, free flap reconstructions are 61 
delayed until 6 months post-RT (e.g. delayed breast reconstruction post-mastectomy)(8). 62 
However, such delays incur more operative procedures(9), multiple hospital admissions for the 63 
patient(10), and, result in aesthetically inferior reconstructive outcomes compared to immediate 64 
reconstructions (11, 12). Consequently, conferring radioprotection to a free flap offers the 65 
clinical benefit of allowing patients undergoing reconstructions after cancer excision to have an 66 
earlier reconstruction, which is more durable against the adverse effects of adjuvant therapies. 67 
Irradiation of the vasculature has been shown to cause endothelial dysfunction, sustained 68 
inflammation, pruning of the vascular architecture and a pro-thrombotic milieu defined by over-69 
expression of plasminogen activator inihibitor 1 (PAI-1)(13-15). It is postulated that the dense 70 
fibrotic reaction in LAEs may represent aberrant, dysregulated, compensatory responses to tissue 71 
hypoxia caused by vascular damage(16). RT-induced reactive oxygen species (ROS) are 72 
implicated(17, 18) in the activation of pro-fibrotic pathways, such as TGF-1 and connective 73 
tissue growth factor (CTGF), and appear to be central to the development of LAEs. Specifically, 74 
altered expression of cellular adhesion molecules (VCAM1/ICAM1)(19), endothelial-to-75 
mesenchymal transition (Endo-MT)(15, 20-22) and over-expression of PAI-1(13-15) are thought 76 
to be central mechanisms that instigate the development of LAEs. ROS are normally inactivated 77 
by the enzyme superoxide dismutase (SOD), which exists in cytoplasmic (SOD1), mitochondrial 78 
(SOD2) and extra-cellular (SOD3) forms. SOD2 gene therapy radioprotects normal cells in vitro 79 
and in vivo(19, 23-30) and has been tested in a phase I clinical trial(31). SOD2 gene therapy 80 
represents an attractive therapeutic strategy as it targets an early step in the pathophysiological 81 
cascade from irradiation to LAEs. CTGF, a downstream effector of TGF1 signaling, is over-82 
expressed in radiation-induced fibrosis(35-37) and other pathological fibrotic states(38-40). 83 
Therefore, we sought to develop a radioprotective therapy to target both oxidative stress (SOD2) 84 
and fibrotic (CTGF) pathways.  85 
The challenge in delivering radioprotective therapies is to target, specifically, normal 86 
tissues and not those that may harbor microscopic residual disease. Clinically, such an 87 
opportunity arises when performing free tissue transfer, for example in the case of immediate 88 
breast reconstruction following mastectomy (41-43). Free flaps are composite blocks of tissue 89 
harvested from distant donor sites on their supplying blood vessels. Radioprotective gene therapy 90 
strategies using plasmid/liposomal, and virally-delivered, SOD2 have been reported previously 91 
(24, 31-34) where vectors are delivered either directly to target organs, or, delivered 92 
intravenously. Due to the central role of the vascular compartment in the development of LAEs 93 
we, therefore, sought to protect selectively the vasculature of normal tissues by delivering 94 
radioprotective vectors intra-arterially into flaps during the ischemic interval. We hypothesized 95 
that over-expressing SOD2 and silencing CTGF would reduce the severity of LAEs in irradiated 96 
normal tissues without compromising the anti-tumour efficacy of RT. We sought to investigate 97 
this using a free flap gene therapy model(43-48) as it permits exquisite anatomic control of viral 98 
delivery and because of its potential for subsequent translation.  99 
 100 
We show that free flap irradiation causes characteristic contracture and volume loss, akin 101 
to those seen in the clinical context. We show that these changes are due to irreversible damage 102 
in the vascular compartment that leads to the generation of tissue hypoxia and fibrosis. We 103 
generate therapeutic lentiviral vectors that mediate durable transgene expression in vivo and 104 
show that SOD2 over-expression and CTGF silencing achieve differential effects in ameliorating 105 
LAEs within irradiated flaps. We demonstrate that SOD2 monotherapy preserves flap volume by 106 
maintaining vascular architecture and function, whereas anti-CTGF monotherapy reduces post-107 
RT cutaneous contracture. Combination therapy with both vectors protects irradiated flaps 108 
against both volume loss and flap contracture. Finally, we show that SOD2 over-expression in 109 
normal tissues does not compromise the efficacy of RT and may indeed enhance it. 110 
111 
Results  112 
Irradiation of SIEA flaps with 50 Gy in 3 fractions produces a clinically-relevant LAE 113 
phenotype characterized by SOD2 depletion, CTGF over-expression and fibrosis 114 
We report a previously undescribed model of free flap irradiation using the superficial 115 
inferior epigastric artery (SIEA) flap in rodents (fig. S1) that we developed specifically to test 116 
our hypotheses. In brief, we trialed 3 biologically-equivalent fractionation schedules and 117 
characterized the LAEs that developed in vivo after irradiation (fig. S1). SIEA flaps irradiated 118 
with 50 Gy/3 fractions developed a clinically-relevant LAE phenotype (fig. S1) characterized by 119 
skin paddle contracture (figure 1A. i-iv), volume loss and pathognomonic skin changes (altered 120 
pigmentation and telangiectasia). Skin paddle surface areas were significantly reduced in 121 
irradiated flaps compared to un-irradiated controls (figure 1 A and B). Irradiated flaps exhibited 122 
acute RT-induced toxicities (fig. S1) ranging from dry desquamation to confluent, moist 123 
desquamation. Acute toxicities (scored using the Radiotherapy Oncology Group (RTOG) 124 
criteria(49)) were evident at day 7,  peaked at day 14 post-RT and resolved by 35 days (figure 125 
1.C.i.). Irradiated flaps attained progressively higher scores on the RTOG LAE criteria (figure 126 
1.C.ii.). Late RTOG scores stabilized by 140 days post-RT with irradiated flaps attaining a mean 127 
score 5.85 (SEM: 0.10) at 180 days. LAEs were first evident in the skin followed by the 128 
subcutaneous tissues and, ultimately, the knee joint (figure 1.C.iii.). Mean passive ROM at 129 
irradiated knee joints was significantly reduced compared to non-irradiated controls (figure 1.C 130 
iv.). Magnetic resonance imaging (MRI) of irradiated, and matched un-irradiated controls in vivo 131 
revealed significant reductions in flap volume at 6 months (figure 1.D.i-iii).  132 
We observed CTGF over-expression (figure 1.E.i and 1.G.i-iii) and functional SOD2 depletion 133 
(figure 1.E.ii) in irradiated flaps. Western blot analyses demonstrated a reduction in SOD2 134 
protein levels and activation of Wnt signaling in irradiated flaps (figure 1.F). Histological 135 
analysis (Masson’s trichrome staining) revealed a dense fibrotic reaction and greater fat necrosis 136 
in irradiated flaps (figure 1.G.i-iii). RT-QPCR analyses demonstrated significant reductions in 137 
CTGF and COL3a1 (p<0.05) expression and increased COL1a2 gene expression (p<0.001) 138 
(figure 1.H.i-iii). Taken together, these data suggest that the LAE phenotype in our model 139 
exhibits clinical, anatomical, volumetric and biological changes similar to those seen in a clinical 140 
setting. 141 
 142 
Irradiated flaps exhibit abnormal vascular function characterized by loss of endothelial 143 
function and fibrosis 144 
Quantitative functional imaging of irradiated and matched un-irradiated flaps 145 
demonstrated significant changes in the MRI transverse relaxation rate R2* of flap tissues 146 
following irradiation (figure 2.A). Briefly, the presence of paramagnetic deoxyhaemoglobin in 147 
erythrocytes creates magnetic susceptibility perturbations around blood vessels, increasing R2* 148 
of the surrounding tissue in proportion to the tissue deoxyhaemoglobin concentration. This non-149 
invasive approach offers a sensitive method of monitoring the dynamics of vascular modeling, 150 
function and regression in vivo(50-52). Prior to irradiation, flaps situated on the left hind limb 151 
(that were due to be irradiated) had a faster R2* than flaps on the contralateral, control hind limb 152 
(p<0.05) (figure 2.B.i). In irradiated flaps, the mean absolute R2* decreased progressively and, 153 
normalized to pre-RT R2* values, stabilized at 56% at 6 months post-RT (figure 2.B.ii). Two-154 
way ANOVA showed these changes to be statistically significant (p=0.0004) and post-hoc 155 
analyses revealed that irradiated flaps had significantly slower R2* values from 1 month post-RT 156 
(p<0.001) (figure 2.Bb.ii) onwards.  157 
To correlate vascular function and structure, we performed immunofluorescence analyses 158 
using markers for perfused (functional) blood vessels (Hoechst 33342), vascular permeability 159 
(Evans blue) and hypoxia (pimonidazole adduct formation). Irradiated flaps demonstrated 160 
significant reductions in functional vasculature (control 34.9% v. irradiated 16.5%; p < 0.001) 161 
and vascular permeability (control 19.4% v. irradiated 3.8%; p < 0.0001) (figure 2.c-f), and 162 
greater hypoxia within the stromal compartment (control 5.2% v. irradiated 16.7%; p< 0.001) 163 
(figures 2.C., D. and G.). Areas of hypoxia were observed surrounding vessels exhibiting a dense 164 
fibrotic reaction (figure 2.G.).  165 
In summary, LAEs are associated with vascular dysfunction characterized by a reduction in R2* 166 
indicating impaired haemodynamic vasculature. This dysfunction is associated with loss of 167 
patent vasculature, peri-vascular fibrosis and tissue hypoxia.  168 
 169 
Development and validation of LVSOD2 and LVshCTGF in vitro and the durability of 170 
lentivirally-delivered transgene expression in vivo  171 
Having demonstrated SOD2 depletion in LAEs in vivo, we investigated how soon after 172 
irradiation this occurred. A time-course study of irradiated fibroblasts showed early and RT 173 
dose-dependent reductions in SOD2 activity (figure 3.A.). We subsequently generated stable 174 
SOD2-overexpressing fibroblast cell lines and showed that SOD2 activity could be significantly 175 
increased from basal levels (fig. S2). SOD2 overexpressing stable cells (RF-LVSOD2) retained 176 
significantly (p < 0.001) greater SOD2 activity than both naïve cells and stable cells generated by 177 
infection with a control vector (RF-LVGFP) post-RT with 8 or 16 Gy (figure 3.B). To 178 
investigate whether this survival effect was apparent across fractionated, in addition to, single-179 
fraction doses we performed MTT assays at 120 hours in endothelial cells (YPEN1) after 180 
irradiation with 3 biologically-equivalent fractionation doses (5 Gy single fraction, 6.4 Gy/2 181 
fractions and 7.2 Gy/3 fractions). We observed significant increases in cell survival across all 182 
fractionation schedules (figure 3.C) and further confirmed this using 3D spheroid assays 183 
(YPEN1) (figure 3.D) where we observed significantly greater preservation of spheroid volume 184 
following RT in cells over-expressing SOD2 (YPEN SOD2). To investigate whether this 185 
survival benefit was specific to SOD2 over-expression we performed transient SOD2 knock-186 
down in YPEN1 cells using siRNA 48 hours prior to RT (figure 3.E). We observed that SOD2 187 
knock-down resulted in reversal of the survival benefit observed previously and PCR 188 
demonstrated significant reductions in SOD2 gene expression using this strategy. Clonogenic 189 
assays in tumour cell lines (HeLa and FaDu) demonstrated inconsistent differences in survival 190 
following irradiation between cells over-expressing SOD2 and controls (figure 3.G. and H.) 191 
(p<0.05). Finally, to investigate whether the radioprotective effects we had observed were being 192 
mediated through the mitochondrial, or cytosolic, localization of SOD2 we performed 193 
immunofluorescent staining for SOD2 in transfected cells using anti-mitochondrial (cytochrome 194 
C oxidase: MTCO1) antibodies (figure 3.I). We observed greater SOD2 expression in cells 195 
infected with LVSOD2 (figure 3.I.ii) and that SOD2 expression co-localised to the 196 
mitochondrial, rather than the cytosolic, compartment. To confirm this, we harvested lysate from 197 
mitochondrial and cytosolic compartments of cells over-expressing SOD2 in a stable manner and 198 
relevant controls (figure 3.I.iii) for analysis of biochemical SOD2 activity. We observed that 199 
SOD2 activity was significantly increased in the mitochondrial compartment (p<0.01) of cells 200 
over-expressing SOD2 but not in the cytosolic compartment.  201 
Briefly, using a second generation lentiviral backbone, we cloned several plasmids 202 
encoding shRNA sequences targeted against rat CTGF and used these to generate a battery of 203 
lentiviral particles by transfection of HEK 293T cells. Lentiviral particles were used to create 204 
stable cell lines (rat fibroblasts) and CTGF knock-down was quantified by ELISA using in vitro 205 
models of basal and stimulated (+ TGF-1) CTGF expression (supplementary figure 2.C. and 206 
D.). We identified a lead candidate shRNA that knocked down both basal, and stimulated, CTGF 207 
to approximately 50% of that seen in naïve, control cells and this was used for further in vivo 208 
investigation.  209 
To investigate whether SOD2 over-expression and CTGF knock-down could be achieved 210 
in vivo, we infected SIEA flaps with LVSOD2 (10
8
 TUs) and LVshCTGF (10
8
 TUs) and 211 
harvested flap tissues 30 days post-operatively - the time point at which flaps would have been 212 
irradiated. We found increased SOD2 protein expression in the SIEA vascular pedicle of 213 
LVSOD2-infected flaps compared to matched, contralateral, control SIEA flap vessels (figure 214 
3.J. i and ii). Using a biochemical activity assay, we confirmed significantly greater SOD2 215 
activity in LVSOD2-infected flaps compared to controls (P < 0.001) (figure 3.J.iii). Flaps 216 
infected concomitantly with LVSOD2 and LVshCTGF showed significantly reduced CTGF 217 
levels compared to controls and those infected with LVSOD2 only (p <0.01) (figure 3.J.iv). As 218 
our therapeutic strategy aimed to target the vascular system, we sought to demonstrate increased 219 
SOD2 activity within the vascular compartment.  We, therefore, dissected out the vascular 220 
pedicle to the flap (SIEA and SIEV) and extracted RNA and protein from this tissue. RT-QPCR 221 
demonstrated significant SOD2 transcript over-expression (figure 3.K) in flaps infected with 222 
LVSOD2 compared to sham controls. This was further validated by functional SOD2 assay 223 
(figure 3.L) that showed LVSOD2-infected pedicles had greater ROS scavenging activity 224 
compared to controls.  225 
Due to the duration over which LAEs manifest in our model, we investigated the 226 
durability of transgene expression in vivo. SIEA flaps were infected with a GFP-expressing 227 
lentiviral vector (LVeGFP) and flap tissues were harvested at 180 days post-infection. We 228 
observed sustained GFP expression in large (SIEA, SIEV) and small vessels (figure 3.M. i-vi). In 229 
addition, we observed GFP expression in extra-vascular tissues, notably adipose (figures 3.E.vii 230 
and viii), skin, muscle and nerve (fig. S2). To quantify viral DNA in flap tissues, we performed 231 
Q-PCR on genomic DNA extracted from flap tissues 180 days post-infection and found 10
4
 232 
relative copies of the lentiviral gag gene per 100 ng of DNA (figure 3.N.).  233 
 234 
Combinatorial gene therapy with LVSOD2 and LVshCTGF in free flaps mitigates the 235 
LAEs of radiotherapy 236 
SIEA flaps infected with LVSOD2 and/or LVshCTGF showed significant improvements 237 
in LAE phenotype, skin paddle contracture, acute and late toxicity scores and flap volume 238 
retention (figure 4). Flaps transduced with LVSOD2 and LVshCTGF exhibited (figure 4.A.i-v) 239 
less pigmentation change and contracture, even in the presence of typical LAE changes (such as 240 
telangiectasia) arising in adjacent skin, outside the zone of viral vector delivery (figure 4.a.iii 241 
(red arrows)). There was no mitigation of RT-induced effects with the scrambled vector control 242 
(LVsh-scram) (figure 4.A.v). Skin paddle contracture was improved significantly in flaps 243 
transduced with both LVSOD2 (relative surface area: 53.8%; p < 0.05) and LVshCTGF 244 
monotherapy (relative surface area: 70.8%; p < 0.0001) compared to controls (PBS sham 245 
(relative surface area: 33.9%) and LVsh-scram (relative surface area: 25.4%). The greatest 246 
improvement occurred in the LVSOD2 and LVshCTGF combination cohort (relative surface 247 
area: 86.5%; p < 0.0001) (figure 4.A.vi and vii).  248 
 249 
Flaps transduced with LVSOD2, alone or in combination, exhibited significant reductions 250 
(p<0.01) in the duration, but not maximum severity, of acute toxicities post-RT (figure 4.B.). At 251 
180 days, SIEA flaps infected with LVSOD2, alone or in combination, showed sustained and 252 
significant reductions in RTOG severity scores (p < 0.05) (figure 4.C.i and iii). Flaps infected 253 
with LV-shCTGF demonstrated early improvements in RTOG severity scores (p< 0.05) but these 254 
were not sustained (figure 4.C.ii). Analysis of the RTOG component scores for skin, 255 
subcutaneous tissues and joint showed that LVSOD2-infected flaps exhibited significant 256 
preservation of subcutaneous volume (figure 4.C.ii and vi.) and a more modest improvement in 257 
skin severity scores. Conversely, LVshCTGF-infected flaps had greater improvements in skin 258 
component scores but scored poorly with regards to subcutaneous volume loss (figure 4.C.iv). 259 
All cohorts scored maximum severity points for joint-related changes, as would be expected 260 
given that joint tissues were extrinsic to the zone of vector delivery. These data demonstrate 261 
differential improvements in skin paddle contracture and flap volume loss attributable to 262 
LVshCTGF and LVSOD2, respectively, suggesting different mechanisms for RT-induced skin 263 
paddle contracture and volume loss. Thus, combination therapy with both LVSOD2 and 264 
LVshCTGF is required for the greatest radioprotective effect.  265 
 266 
In vivo MRI demonstrated significant improvements in flap volume only in those flaps 267 
transduced with LVSOD2, either alone or in combination (p<0.0001) (figure 4.D.i-vi) compared 268 
to controls. Analysis of functional MRI data also demonstrated that flaps transduced with 269 
LVSOD2, alone or in combination, demonstrated normalization of R2* towards that seen in 270 
unirradiated flaps (p=0.0004) (figure 4.D.vii). Taken together, these data support the earlier 271 
findings that LVSOD2 therapy is responsible for the preservation of flap volume post-RT and 272 
that this is associated with preservation of the vasculature. 273 
 274 
To investigate whether SOD2 levels remained elevated in irradiated flaps, Western blot 275 
analyses were performed (figure 5.A.) and showed preservation of SOD2 protein levels in 276 
irradiated flaps infected with LVSOD2 compared to those infected with LVshCTGF and 277 
controls.  278 
 279 
Masson’s trichrome staining of irradiated flaps demonstrated greater fibrosis in control 280 
flaps compared to those infected with LVSOD2 and LVshCTGF, either alone or in combination 281 
(p<0.0001). Post-hoc analysis revealed that flaps infected with LVSOD2 (% fibrosis 7.8%) and 282 
LVshCTGF (% fibrosis 7.9%) monotherapy exhibited significantly less fibrosis post-irradiation 283 
(p<0.0001) compared to sham (% fibrosis 35.0%) and scrambled controls (% fibrosis 29.4%). 284 
Flaps infected with LVSOD2 plus LVshCTGF combination therapy exhibited significantly less 285 
fibrosis (% fibrosis 1.7%) than those receiving either agent as a monotherapy (p<0.05) and the 286 
burden of fibrosis was found to be no different compared to unirradiated flaps (p>0.05) (figure 287 
5.B. and C.i.). Reverse transcriptase Q-PCR (RT-QPCR) revealed significant reductions in 288 
col1a2 gene expression in flaps infected with LVSOD2, either alone or in combination (p<0.01) 289 
compared to controls (figure 5.C.ii). Interestingly, flaps infected with LVshCTGF alone did not 290 
demonstrate reduced col1a2 gene expression despite exhibiting reductions in fibrosis compared 291 
to sham and scrambled controls (fig.5.C.ii).  292 
 293 
Functional vascular analyses demonstrated reductions in perfused vasculature (Hoechst 294 
33342) and permeability (Evans blue), and the presence of stromal hypoxia (pimonidazole) in 295 
irradiated flaps, as described earlier. However, flaps infected with LVSOD2, either alone or in 296 
combination, demonstrated significantly greater Hoechst 33342 uptake (p<0.0001), Evans blue 297 
leakage (p<0.0001) and significantly less pimonidazole adduct formation (p<0.0001) compared 298 
to sham and scrambled controls (figure 5.D. and E.). Flaps infected with LVshCTGF alone 299 
demonstrated levels of Hoechst 33342 uptake not dissimilar to sham (PBS) controls but 300 
significantly greater than scrambled controls (p<0.01) and similar levels of pimonidazole 301 
staining compared to irradiated, but untreated, flaps. However, LVshCTGF-infected flaps 302 
exhibited significantly greater Evans blue leakage compared to irradiated controls, but 303 
significantly less staining than flaps infected with LVSOD2 (either alone or in 304 
combination)(p<0.001) and un-irradiated controls (p<0.0001) (figure 5.D. and E.). Taken 305 
together, these data suggest that LVSOD2 protects against the development of LAEs through 306 
preservation of vascular function as demonstrated by the observed improvements in perfused 307 
vasculature and vascular permeability following irradiation, and the associated reduction in 308 
hypoxia. The contribution of LVshCTGF in this context is that of preserving vascular 309 
permeability although this is not to the same degree as that observed with LVSOD2 therapy and 310 
does not correlate with a reduction in the development of tissue hypoxia following irradiation. 311 
To investigate to what extent both viral vectors co-localized within the vascular compartment of 312 
the flap we performed multi-plexed immunofluorescent staining for GFP (LVshCTGF) and RFP 313 
(LVSOD2) (figure 5.F). We observed dual infection of endothelial cells with both vectors (figure 314 
5.F) but also observed extra-vascular co-localization. Cells that had been infected with a single 315 
vector only were infrequent.  316 
 317 
LVSOD2 therapy in normal tissues does not compromise the anti-tumour efficacy of 318 
radiotherapy 319 
Because of concerns that SOD2 over-expression in stably transduced flap tissues might 320 
lead to increased survival of microscopic residual disease (MiRD) through release of SOD2, we 321 
performed conditioned medium experiments taking supernatant from HeLa-LVSOD2 “producer” 322 
cells and using it to inoculate naïve HeLa “target” cells. We found no evidence that SOD2 was 323 
transmitted between cell types (figure 6.A.).  324 
To elucidate the effects of tumour bed irradiation through a flap expressing 325 
radioprotective genes, we developed an in vivo model of tumour recurrence within rodent SIEA 326 
flaps. Briefly, flaps were transduced (PBS sham, LVSOD2 and LVeGFP; n = 5 per group) and, 327 
at a later date, engrafted with syngeneic MatBIII tumour cells 26 days post-operatively (figure 328 
6.B). Established tumours were irradiated (20 Gy/5 fx) and tumour growth and animal survival 329 
were recorded. Untreated tumours growing in sham-transduced flaps grew rapidly to humane 330 
end-point. Tumours irradiated in sham-transduced flaps exhibited growth delay, but 4 of 5 331 
tumours ultimately grew to humane end-point. Tumours irradiated in LVSOD2-infected flaps 332 
exhibited significant reductions in tumour growth (figure 6.C.). Of this group, 4 of 5 tumours 333 
achieved complete remission to 40 days (figure. 6.D.iii.). We repeated the experiment using a 334 
control lentiviral vector (LVeGFP) and tumour growth closely mirrored that seen in the sham-335 
transduced group (figure. 6.D.iv). Survival to humane end point was also significantly prolonged 336 
in the LVSOD2 group compared to sham- and LVeGFP-transduced controls (p < 0.0001) (figure 337 
6.E.). 338 
In summary, these data support our hypothesis that SOD2-mediated radioprotection of 339 
normal tissues does not compromise the anti-tumour efficacy of RT on MiRD. Indeed, normal 340 
tissue radioprotection may modulate favourably the RT response through manipulation of the 341 
normal tissue microenvironment.  342 
 343 
Discussion  344 
The development of LAEs within normal tissues poses a challenging clinical problem, 345 
irrespective of the tissues in which they may arise. The prevalence of LAEs in irradiated free 346 
flaps has been reported to be as high as 60% in some series(6). Therefore, where the option 347 
exists, surgeons frequently choose to defer reconstruction until after the completion of 348 
radiotherapy. LAEs in irradiated flaps have a significant adverse impact on cancer survivorship 349 
by necessitating further surgery years after cancer treatment is complete. Protecting free flaps 350 
from the adverse effects of radiotherapy represents an attractive therapeutic strategy. In 351 
conjunction with the clinical imperative, the technical procedure of performing a free flap also 352 
offers a distinct therapeutic window for the delivery of viral gene therapies in a manner that is 353 
exquisitely anatomically controlled. This concept of “free flap gene therapy” was first described 354 
using a liposomal vector carrying the VEGF gene(53) but later characterized extensively by 355 
Gurtner’s group(45, 46). Unlike systemically-delivered viral gene therapies, free flap gene 356 
therapy has fewer potential barriers to success because the viral vectors are not exposed to the 357 
systemic circulation, thereby reducing specific and non-specific immune neutralisation, they by-358 
pass the reticuloendothelial system and can be delivered in high titres exclusively to target 359 
tissues(54). In the current work, therefore, we used a combinatorial radioprotective strategy by 360 
directing lentivirally-delivered transgenes into flap tissues ex vivo before irradiation. 361 
 362 
Radiation-induced reactive oxygen species (ROS) mediate their effects over a hyperacute 363 
time frame and SOD2 over-expression represents a very proximal point for therapeutic blockade 364 
of LAEs(19, 23-26, 30, 32). Previous work has demonstrated the efficacy of a SOD2 gene 365 
therapy strategy delivered topically as a plasmid/liposome (23, 25, 26, 31, 55), packaged in an 366 
adenoviral vector (30) or delivered systemically (34, 56). In contrast, CTGF exerts its effects 367 
over a more prolonged time course, as seen by its involvement in fibrotic disease states, 368 
including cirrhosis, systemic sclerosis, pulmonary, renal fibrosis, and chronic transplant 369 
rejection. CTGF over-expression has been demonstrated in tissues exhibiting LAEs, but this has 370 
largely been independent of raised TGF-1 expression and Smad signaling(18, 37). Alternative 371 
signaling mechanisms, such as Rho/ROCK, drive CTGF expression in this context, and 372 
pharmacological intervention (e.g. statins as Rho/ROCK inhibitors) has reversed the established 373 
LAE phenotype in animal models(57, 58). CTGF-targeted therapies aim to reduce the drive to 374 
fibrosis and, thus, represent a distal therapeutic blockade of LAEs (40). Having observed 375 
reductions in SOD2 expression/activity and CTGF over-expression in our rodent model, we 376 
designed a dual-targeted preventative approach to augment the oxidative stress response and 377 
block fibrosis.  378 
 379 
We developed a novel model of free flap irradiation in order to test our hypotheses. We 380 
showed that irradiating flaps with 50 Gy/3 fractions recapitulated the clinical development of 381 
LAEs with prominent contracture, volume loss, fibrosis and activation of relevant signaling 382 
pathways (figure 1). In addition, we were able to show that LAEs were associated with impaired 383 
vascular function as quantified by loss of perfused vasculature, vascular permeability and the 384 
subsequent development of stromal hypoxia (figure 2). As such, this model represents an 385 
excellent platform in which to test preventative and therapeutic strategies. Subsequently, we 386 
generated and validated LVSOD2 and LVshCTGF vectors in vitro and confirmed that 387 
mitochondrial SOD2 over-expression is associated with increased survival post-radiotherapy in 388 
vitro (figure 3. A-F and I) across a range of fractionation schedules. Using transient knock-down 389 
of SOD2 gene expression with siRNA, we demonstrated a reversal of the radioprotective effect 390 
of SOD2 over-expression (figure 3.E). In validating this strategy in vivo, we were able to 391 
demonstrate that SOD2 is over-expressed and CTGF concentrations are reduced following 392 
lentiviral infection (figure 3. J-L), SOD2 over-expression particularly is evident within the 393 
vascular compartment of flaps (figure 3. K and L) and that infection with a combination of 394 
lentiviral vectors leads to co-localization of infectivity (figure 5.F).  395 
Importantly, by using conditioned medium experiments, we were able to prove that over-396 
expression of mitochondrial SOD (SOD2) in normal tissues of the flap would not provide a 397 
soluble, released mediator of radioprotection in neighbouring tumour cells (Figure 6.A). 398 
Infection with LVSOD2 and LVshCTGF were shown to result in functional gains in SOD2 399 
activity and reductions in CTGF concentration, respectively. We then developed a model of 400 
tumour (rodent breast adenocarcinoma) recurrence in SIEA flaps infected with LVSOD2 or a 401 
vector control (LVeGFP) in order to test the efficacy of irradiating tumour cells in the context of 402 
a radioprotected normal microenvironment (figure 6.B.). Interestingly, tumours growing in 403 
LVSOD2-infected flaps had a more favourable response to radiotherapy (median survival not 404 
reached) compared to those irradiated in sham-infected (PBS) flaps (median survival = 27 days). 405 
To investigate whether this might be due to enhanced immune surveillance within flap tissues, as 406 
a non-specific effect of lentiviral infection, we repeated the experiment with a vector control 407 
(LVeGFP) and observed similar disease progression to that seen in the sham cohort (median 408 
survival = 25 days) (figure 6). These data prove that radioprotecting normal flap tissues will not 409 
compromise the anti-tumour efficacy of radiotherapy, and indeed may modulate favourably the 410 
tumour microenvironment to enhance treatment efficacy. The mechanisms underlying this 411 
observation are at present unclear, and the subject of ongoing work, however, previous authors 412 
have reported the direct, anti-tumour effects of SOD2 over-expression that are thought to be 413 
mediated by metabolic intermediaries (e.g. superoxide or hydrogen peroxide), inhibition of 414 
vascular endothelial growth factor and epigenetic modification (59-63). However, in the context 415 
of our model, where tumours are not directly infected with LVSOD2, we favour an 416 
immunological hypothesis. That is, in the presence of normal tissue radioprotection with 417 
LVSOD2, fewer distracting, immunological signals are generated after RT leading the immune 418 
response to target those cells that are not radioprotected, i.e. tumor cells.  419 
 420 
We monitored the durability of transgene expression in lentivirally-infected free flaps 421 
using GFP and saw robust levels of gene expression out to 180 days. We tested LVSOD2 and 422 
LVshCTGF, both as mono- and combination therapies in our LAE model. Although LVSOD2 423 
and LVshCTGF individually improved the LAE phenotype, the greatest gains, as judged by 424 
clinical parameters, were achieved by combining the two agents. Interestingly, the two vectors 425 
appeared to exert differential improvements on the LAE phenotype: LVSOD2 was more 426 
efficacious in preserving flap volume and vascular function, whilst LVshCTGF was more 427 
effective in preventing skin/flap contracture (figure 4). These improvements were associated 428 
with significant reductions in fibrosis when delivered as monotherapies, and in an additive 429 
fashion when used as a combination approach (figure 5. B. and C.). Finally, we were able to 430 
confirm that improvements in flap volume with LVSOD2 therapy (either alone or in 431 
combination) were due to preservation of vascular function and the subsequent reduction in 432 
stromal hypoxia (figure 5. D. and E.). The contribution of CTGF knock-down to the mitigation 433 
of LAEs is interesting and is most evident when considering flap skin paddle contracture (figure 434 
4. A.) and stromal fibrosis (figure 5.B. and C.). From the functional vascular analysis, 435 
LVshCTGF monotherapy resulted in significant improvements in vascular permeability (figure 436 
5. E. ii), but this did not result in significant reductions in stromal hypoxia compared to controls 437 
(figure 5. E. iii). Taken together, these data suggest that CTGF blockade reduces both stromal 438 
and peri-vascular fibrosis but this, on its own, is insufficient to prevent the development of 439 
hypoxia, presumably as a result of impaired endothelial function that LVshCTGF monotherapy 440 
does not prevent.  441 
 442 
Structurally, irradiation of the vasculature causes a dose-dependent destruction of blood 443 
vessels, which particularly affects the microvasculature(64-68). The loss of vascular density 444 
increases the distance between functioning vessels, meaning that some parenchymal tissues fail 445 
to be perfused. In the longer-term, irradiated blood vessels become thicker, primarily due to 446 
intimal thickening, and develop a propensity to atherosclerosis. It has been proposed(69) that the 447 
cumulative effects of endothelial dysfunction and death, after irradiation, lead to a breakdown in 448 
transport functions and trigger a self-propagating cycle of inflammation (mediated by cytokines 449 
such as tumour necrosis factor alpha (TNF-) and ROS), cellular proliferation and fibrosis. At a 450 
microvascular level, previous studies have shown sustained, acute inflammation of vasculature 451 
following irradiation associated with nuclear factor kappa-B (NF κB) activation and over-452 
expression of plasminogen activator inhibitor 1 (PAI-1) (13, 15), as well as differential 453 
regulation of SOD2 expression in irradiated arteries(70). Furthermore, elegant studies using 454 
recombinant mice, homozygous deletion negative for endothelial adhesion molecules (ICAM1, 455 
VCAM1, E-selectin and L-selectin), (71) have shown that L-selectin
-/-
 mice had increased 456 
survival and reduced pulmonary fibrosis after thoracic irradiation. This work demonstrates a 457 
central role for the endothelial compartment in mediating cellular responses to RT and future 458 
work might seek to investigate how SOD2 over-expression modulates adhesion molecule 459 
expression to regulate differentially immune and haematopoietic cell trafficking after RT. In the 460 
current model, loss of vascular function resulted in stromal hypoxia that was most evident 461 
around vessels exhibiting a dense fibrotic reaction (figure 2. G.). We postulate that perivascular 462 
fibrosis observed in LAEs may, therefore, represent a dysregulated compensatory mechanism to 463 
overcome the loss of microvascular function. The preservation of vascular function, through 464 
SOD2 over-expression after radiotherapy, had a significant effect in preserving the normal 465 
phenotype even as a single agent therapy. This may be due to the fact that intra-arterial delivery 466 
of a viral vector, which is the most effective way of achieving diffuse transgene expression 467 
across all flap tissues(48), achieves the greatest multiplicity of infection (MOI) for the cells of 468 
the vascular tree as they are the cells of first contact for the viral particles.  469 
 470 
In conclusion, these data provide preclinical evidence to support a combination strategy 471 
to augment proximal, oxidative stress responses within the vascular compartment, and mitigate 472 
distal, end-stage fibrosis reactions in post-radiation LAEs in irradiated free flaps. These 473 
therapeutic goals can be combined additively and can be achieved without compromising the 474 
anti-tumour efficacy of radiotherapy. Translation of this concept is feasible within the constraints 475 
of the technical considerations of free flap surgery and may allow for patients to be offered 476 
earlier reconstructions that are more durable against the side effects of adjuvant cancer therapies.  477 
 478 
479 
Materials and Methods 480 
Surgical model 481 
Under inhalational anaesthesia, superficial inferior epigastric artery (SIEA) flaps were 482 
raised in Fischer (F344) male rats (250g) (Harlan Laboratories, Huntingdon, UK) as described 483 
previously(72). Viral vectors (1x10
8
 transducing units (TUs)) were delivered into flaps by intra-484 
arterial injection through a 27G cannula along with 1 g recombinant rat vascular endothelial 485 
growth factor A (VEGF-A), in a total injection volume of 500 L. Viral particles were left to 486 
incubate for 50 minutes before the vascular compartment was flushed through and vascular 487 
anastomoses performed to re-establish blood flow within the flap. The flap was inset into the 488 
ventral hind limb of the animal and the animal recovered. All animal experiments were 489 
conducted in accordance with institutional and Home Office (PL: 70/7947) regulations.  490 
 491 
SIEA flap irradiation 492 
Flap irradiation was performed 30 days post-operatively under anaesthesia (i.p. 10 493 
mg/mL fentanyl and 5 mg/mL midazolam). Rats were placed in a radioprotective lead shield (6 494 
mm) containing an aperture under which the flap could be positioned. Irradiation was performed 495 
using an orthovoltage (250 kV) X-ray machine (AGO, Reading, UK). Irradiation was performed 496 
at 250 kV, 11 milliamps and at a dose rate of 4.5 Gy/min. Animals were maintained for serial 497 
clinical measurements for skin paddle contracture and RTOG severity scores for 180 days post-498 
irradiation. At 180 days, flap tissues and contralateral control tissues were harvested for analyses 499 
under terminal anesthesia.  500 
 501 
Tumour recurrence model 502 
Animals underwent SIEA flap procedures as described above. Rat MatB III breast 503 
adenocarcinoma cells (ATCC, Teddington, UK) were trypsinised, pelleted and counted. 1 x 10
7
 504 
cells were prepared for injection into each animal. Cells were washed and centrifuged 3 times in 505 
and re-suspended in a volume of 250 L for injection. On the 26th post-operative day, cells were 506 
injected directly into the SIEA flap and monitored daily for tumour growth. Tumours were 507 
irradiated with 20 Gy in 5 consecutive, daily fractions when they reached a diameter of 1 cm.  508 
 509 
Clinical outcomes 510 
Skin paddle dimensions along the long (x) and short (y) axes of the skin paddle were 511 
quantified by caliper measurements between tattooed points. Skin paddle surface area was 512 
estimated using the formula: area = 0.8*(xy). Early and late adverse effects were scored 513 
according to the Radiation Therapy Oncology Group (RTOG) adverse effects criteria(49).  514 
 515 
In vivo MR imaging 516 
For MRI, rats were anaesthetised with isoflurane and positioned within a 64 mm i.d. 517 
birdcage 
1
H coil in a 7 Tesla horizontal bore microimaging system (Bruker Biospin, Ettlingen, 518 
Germany).  Morphological multi-slice RARE fat-suppressed T2-weighted axial images were first 519 
acquired for both localization of and subsequent determination of the flap volume.  Contiguous 520 
1mm thick images were acquired over a 6x6cm field of view (FOV), using a 128 by 128 matrix, 521 
a repetition time (TR) of 4500ms, an echo time (TE) of 33ms, and 4 averages, giving an overall 522 
acquisition time of 4 minutes and 48 seconds.   To quantify R2*, multiple gradient echo (MGE) 523 
images were then acquired from three 1.56mm thick transverse slices through the pedicle, using 524 
8 averages of 128 phase encoding steps over a 66cm field of view, giving a temporal resolution 525 
of 3.5 minutes.  MGE images were acquired using a train of 8 echoes spaced 3.14ms apart, initial 526 
TE = 6.21ms, flip angle  = 45 and TR = 200ms. Tumour R2* maps were calculated from the 527 
MGE images by fitting a single exponential to the signal intensity echo time curve on a voxel-528 
by-voxel basis using a Bayesian maximum a posteriori approach(73). All post-hoc MRI 529 
processing and image reconstructions were performed using either OsiriX DICOM Viewer 530 
(OsiriX Foundation, Geneva, Switzerland) or in-house software (Imageview, developed in IDL, 531 
ITT Visual Information Systems, Boulder, CO, USA). 532 
 533 
Functional vascular staining 534 
Changes in vascular function were probed using a markers for perfused blood vessels 535 
(Hoechst 33342 (Sigma-Aldrich, Gillingham, UK)), vascular permeability (Evans Blue (Sigma-536 
Aldrich, Gillingham, UK) and hypoxia (pimonidazole) (74) (Hypoxyprobe, Burlington, USA). 537 
At the experimental end point, animals were anaesthetized using inhalational isoflurane. Forty-538 
five minutes prior to euthanasia, animals were administered Evans blue (i.v. 50mg/kg) and 539 
pimonidazole (i.p. 80mg/kg) and kept warm on a heated mat. Following this, Hoechst 33342 (i.v. 540 
15mg/kg) was administered and a minute later euthanasia was performed. Flaps were harvested 541 
and frozen over liquid nitrogen. Non-consecutive 10m sections were cut from frozen specimens 542 
and fixed in ice cold acetone for 10 minutes, covered in PBS and fluorescent imaging for 543 
Hoechst 33342 and Evans blue performed at 365nm and 520-550nm respectively using a 544 
motorized scanning stage (Prior Scientific Instruments, Cambridge, UK) and a BX51 microscope 545 
(Olympus Medical, Southend, UK). Images were acquired using CellP software (Soft Imaging 546 
System, Munster, Germany). The same slides were then washed in PBS and blocked in 200L of 547 
an immunofluorescence (IFF) buffer for 1 hour at room temperature. Samples were incubated 548 
with a FITC-conjugated anti-pimonidazole primary antibody (1:200 in IFF) overnight at 4C. 549 
The following day slides were washed in PBS and sections covered in PBS prior to pimonidazole 550 
imaging. Images were acquired at 450-499nm as described above using the same stage co-551 
ordinates and, finally, the sections were stained with haematoxylin and eosin (H&E). Images of 552 
sections were acquired from 3 non-consecutive sections taken from each processed flap. The area 553 
of the section expressing Hoechst 33342, Evans blue and pimonidazole adduct fluorescence was 554 
quantified on whole section composite images and expressed as percentage of whole section 555 
(mean % section stained).  556 
 557 
Lentiviral vectors 558 
The LVSOD2 plasmid was created by Capital Biosciences (pLV_III_SOD2) (Capital 559 
Biosciences, MD, USA) for use in vitro and in vivo and control plasmids (LVeGFP) encoding 560 
acquired from the same source. Second-generation packaging plasmids were used for the 561 
production of all in-house viral particles (Addgene, Cambridge, MA, USA).  562 
 563 
For CTGF knock down, the HIVSiren plasmid (kindly donated by Professor Greg 564 
Towers, University College London), constructed with either eGFP or puromycin-resistance 565 
cassettes, was used. This plasmid is derived from a parent plasmid, CSGW (Prof Adrian 566 
Thrasher, University College London)(75).  567 
 568 
CTGF knock down 569 
The rat CTGF mRNA sequence (NCBI: NM_022266.2) was used to obtain knock down 570 
target sequences using an online RNAi target locator tool 571 
(http://www.clontech.com/GB/Support/xxclt_onlineToolsLoad.jsp?citemId=http://bioinfo.clonte572 
ch.com/rnaidesigner/sirnaSequenceDesignInit.do&section=16260&xxheight=1100). The 573 
specificity of these sequences were checked by cross referencing them against known rat 574 
genomic DNA sequences and a non-silencing, scrambled RNAi sequences was also generated 575 
Hairpins were designed to include BamHI (GGATCC) and EcoRI (GAATTC) overhangs at the 576 
5’ and 3’ ends, respectively, as well as the MluI restriction site (ACGCGT) within the hairpin 577 
sequence itself.  578 
 579 
 580 
Generation ofp LVshCTGF and pLVshSCRAM 581 
Oligonucleotides encoding the shRNA sequences were annealed by adding 2.5 L 2 M 582 
sodium chloride solution to 10 L of each oligonucleotide. The mix was heated for 5 minutes at 583 
98C and then slowly cooled at 0.1C per second until 4 C before adding 350 L RNase-free 584 
water, 40 L 3 M sodium acetate, 1.1 mL absolute ethanol and incubated at -80C overnight. 585 
The following day the annealed oligonucleotides were thawed and spun in a table-top centrifuge 586 
at 13,000 rpm, for 45 minutes at 4C. The supernatant was then aspirated and the pellet air-dried 587 
before reconstitution in 50 L RNase-free water. 588 
 589 
A double restriction digest was performed on the HIVSiren backbone using BamHI and 590 
EcoRI (New England Biolabs, Hitchin, UK). In brief, 5 g of HIVSiren plasmid DNA was 591 
digested with 10 units of BamHI (2 L), 10 units of EcoRI (2 L), 5 L EcoRI buffer and 0.5 L 592 
10X bovine serum albumin (BSA) made up to a total volume of 50 L. The reaction was then 593 
incubated in a water bath at 37C for 90 minutes. Following this, 10 L of X6 bromophenol blue 594 
gel-loading dye was added to the reaction and gel electrophoresis performed using a 1% agarose 595 
gel (in 100 mL Tris/Acetic acid/EDTA buffer + 20 L ethidium bromide). Electrophoresis was 596 
performed at 100 V for 45 minutes and DNA bands were visualized using a 302 nm ultraviolet 597 
transilluminator. Bands that demonstrated a linearization event were excised and DNA extracted 598 
from these using a commercially-available DNA extraction kit for subsequent ligation reactions.   599 
 600 
Ligation reactions were performed using: 120 ng of vector DNA, annealed 601 
oligonucleotide insert DNA (at a 1:3 and 1:5 molar ratio), 0.2 L DNA T4 ligase 602 
(ThermoScientific, Fischer Scientific UK Ltd., Loughborough, UK), 2 L ligase buffer and 603 
diethylpyrocarbonate-treated (DEPC-treated) water (ThermoScientific, Fischer Scientific UK 604 
Ltd., Loughborough, UK) to a total volume of 20 L. Ligations were carried out for 15 minutes 605 
at room temperature alongside negative controls consisting of vector DNA only. Ligation 606 
reactions (5 L) were used to transform DH5-™ competent cells (50 L) (Invitrogen, Life 607 
Technologies Ltd., Paisley, UK) using a heat-shock method. Following this, organisms were 608 
recovered by the addition of 200 L of SOC medium (2% tryptone, 0.5% yeast extract, 10 mM 609 
NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, and 20 mM glucose) (Invitrogen, Life 610 
Technologies Ltd., Paisley, UK) and plated at serial dilutions (1:10-1:1000) on ampicillin (50 611 
mg/mL) L-agar plates overnight. The next day single colonies were picked from each plate and 612 
used to inoculate a starter culture of 5 mL Terrific broth (+100 g/mL ampicillin (Sigma-613 
Aldrich, Gillingham, UK); CSSD, ICR, Chelsea, London). This was incubated at 37ºC and 614 
shaken at 220 rpm overnight, following which bacteria were pelleted and DNA extracted using 615 
the Qiaprep© Spin Miniprep kit (Qiagen Ltd., Manchester, UK).DNA was sent for sequencing 616 
using a primer-based protocol (sequencing primer: 5’ 617 
ATGCCAATTGCTCCTTCTCTAGGCGCCGGAAT 3’). Sequences were analysed using 618 
Sequencher 4.8 (Ann Arbor, MI, USA) and cross-checked against hairpin sequences to ensure 619 
the correct sequence and orientation before using the DNA for lentivirus production. 620 
 621 
Generation of LVshCTGF and LVshSCRAM 622 
HEK 293T cells (4 x 10
6
) 
 
were plated in a tissue culture dish and transfections performed 623 
the following day if cells were greater than 80% confluent. 
 
624 
 625 
Transfections were performed using the Lipofectamine
®
 2000 protocol using lentiviral 626 
backbone plasmids (pLVshCTGF, pLVSCRAM, pLV_III_SOD2) (CBS) (Capital Biosciences 627 
Ltd, Rockville, MD, USA) and 2
nd
 generation packaging co-plasmids (psPAX2 and pMD2.g 628 
(Addgene, Cambridge, MA, USA). A Lipofectamine
®
/Opti-MEM
®
 (Life Technologies, Paisley, 629 
UK) mix was made and combined with a DNA/Opti-MEM
®
 mix and allowed to incubate at 630 
room temperature for 5 minutes. The medium from the HEK 293T cells was removed and 631 
replaced with fresh medium and the Lipofectamine
®
/DNA/Opti-MEM
® 
mixture was added to the 632 
plate drop-wise. The plate was incubated at 37C overnight in an incubator (95% air and 5% 633 
CO2) and the following morning the transfection medium was removed and replaced with 634 
collection medium (OptiMEM® + 1:20 cholesterol + 2 mM l-arginine and 1% 635 
penicillin/streptomycin). Supernatant containing viral particles was harvested up to 72 hours 636 
after this time and filtered through a 0.45 m filter (Life Technologies, Paisley, UK).  637 
 638 
Viral particles were concentrated using an ultracentrifugation method (UCF) with a 639 
sucrose cushion. UCF tubes (Thinwall, Ultra-Clear™, 38.5 mL, 25 x 89 mm; Beckman, High 640 
Wycombe, UK) were part filled with viral supernatant and a 25% sucrose solution (25.4 g of 641 
sucrose (Sigma-Aldrich, Gillingham, UK) to a volume of 100 mL with sodium phosphate buffer 642 
(50 mM, pH 7.4) and filter-sterilized) was pipetted into the tube as an underlay. Centrifugation 643 
was performed at 23,000 rotations per minute (rpm) for 2 hours at 4C in a vacuum. The pellet 644 
was re-suspended in 1 mL PBS. 645 
 646 
Lentiviral titres were quantified using a functional, GFP expression assay following the 647 
infection of target cells. On day 1, 1 x 10
5
 HeLa cells/well were plated on a 24-well plate in 648 
DMEM (5% FCS + 2 mM l-arginine + 1% penicillin/streptomycin). The following day 649 
inoculation was performed using serial dilutions (1:100-1:10,000) of viral supernatant (400 L) 650 
(+ 1 g/mL polybrene). Cell counts were also performed across 3 wells and averaged to give a 651 
target cell population at the time of infection. The next day the inocula were aspirated and the 652 
wells replenished with fresh medium. On day 5, the cells were trypsinised and re-suspended in a 653 
2 mL of medium for fluorescence-activated cell sorting (FACS) using the BD LSR II FACS 654 
machine (BD Biosciences, Oxford, UK). A threshold of 3-fold above background signal was 655 
used to gate for GFP positive cells. Following quantification of GFP expression, the titre (in 656 
transducing units per mL) was calculated using the following formula: Titre (TUs / mL) = [(% 657 
GFP
+
 cells/100) x (no. cells per well/volume inoculum)] x dilution. The final titre was calculated 658 
as the average of triplicate assays.  659 
660 
Supplementary Materials 661 
Fig. S1. Development and validation of a novel model of free flap LAEs. 662 
Fig. S2. Validation of CTGF knock down using LVshCTGF.  663 
Materials and Methods 664 
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Figures:  688 
689 
Fig. 1. Irradiation with 50 Gy/3 fractions generates a LAE phenotype characterized by 690 
SOD2 depletion and CTGF over-expression.  691 
 692 
 693 
 694 
 695 
Figure 1. Irradiation with 50 Gy/3 fractions generates a LAE phenotype characterized by 696 
SOD2 depletion and CTGF over-expression. A) Representative photographs of 697 
bilateral SIEA flaps (edges tattooed in Indian ink) inset onto the hind limbs of Fischer 698 
(F344) male rats taken at 180 days after irradiation. The left limb flaps (ii and iv) were 699 
irradiated with 50 Gy/3 fractions on consecutive days whereas flaps on the contralateral 700 
limb did not undergo irradiation. Flap skin paddles were not significantly different prior 701 
to irradiation. Characteristic LAE features were observed in irradiated flaps including 702 
contracture, induration of the skin, telangiectasia and hair loss (un-irradiated flaps have 703 
been shaved to expose marked edges, whereas irradiated flaps have not) (supplementary 704 
figure 1). B) Changes in skin paddle surface area of irradiated and control SIEA flaps 705 
demonstrating significant losses in absolute (i) and relative (ii) skin paddle surface area 706 
( 95% CI). Irradiated flaps were observed to lose up to 70% of their pre-irradiation skin 707 
paddle surface area (p<0.0001). C) Acute and late RTOG scores. i) Acute RTOG scores 708 
(mean  SEM) demonstrating the duration and severity of acute toxicities observed in 709 
flaps irradiated with 50 Gy/3 fx. ii) Late RTOG scores (mean  SEM) in flaps irradiated 710 
with 50 Gy/3 fx demonstrating progressive severity of LAEs in irradiated flaps. iii) 711 
Component scores for the RTOG late effects scores demonstrating that LAEs were first 712 
evident in the skin followed by the subcutaneous tissues and joint. iv) Passive ROM at 713 
the knee joint in irradiated and non-irradiated hind limbs demonstrating a significant 714 
reduction in knee joint excursion in irradiated hind limbs compared to controls. [*** p < 715 
0.0001]. D) i) T2-weighted MR image of bilateral SIEA flaps showing an irradiated flap 716 
(left) and un-irradiated control (right) at 180 days after irradiation (flaps outlined in 717 
green). Note the apparent shrinkage in flap cross-sectional area in the irradiated flap 718 
compared to control. ii) Mean MRI-derived absolute flap volume ( 95% CI) showing 719 
significant flap volume loss in irradiated flaps. iii) Relative MRI-derived flap volume 720 
changes (normalized to pre-irradiation volumes) ( 95% CI) demonstrating that irradiated 721 
flaps lose up to 50% of their pre-irradiation volume by 6 months. [* p < 0.05, *** p < 722 
0.0001]. E) i) CTGF ELISA on flap tissues taken from both irradiated and control flaps 723 
(180 days post-RT) demonstrating an increase in CTGF protein concentration in 724 
irradiated flaps. ii) SOD2 activity measurement by biochemical assay demonstrating a 725 
significant reduction in SOD2 activity in irradiated flaps (52% decrease) compared to 726 
controls. [** p < 0.01]. F) Western blotting of matched control and irradiated SIEA flaps 727 
(at 180 days post-RT) showing reductions in SOD2 protein expression (upper panel) and 728 
activation of Wnt-signalling through phosphorylation of GSK-3. G) 729 
Immunohistochemical analysis of irradiated flaps (180 days post-RT) with Masson’s 730 
trichrome (i-iii), CTGF (iv-vi) and fat necrosis (vii-ix) demonstrating significant 731 
increases in collagen deposition (i and ii; green staining), CTGF (iv and v) and fat 732 
necrosis (vii and viii; red dashed circle). Graphs represent mean  SEM of counts per 733 
high powere field (hpf) or % section exhibiting fat necrosis. H) RT-QPCR for CTGF, 734 
Col1a2 and Col3a1 gene expression (mean fold increase in gene expression  SEM) 735 
(flaps harvested at 180 days post-RT) demonstrating significant reductions in CTGF and 736 
Col3a1 expression but significant increases in Col1a2 gene expression [*p<0.05, 737 
**p<0.01, **** p < 0.0001].  738 
 739 
 740 
741 
Fig. S1. Development and validation of a novel model of free flap LAEs 742 
 743 
 744 
 745 
Fig. S1. Development and validation of a novel model of free flap LAEs. A) The surgical 746 
superior inferior epigastric artery (SIEA) flap model. Main photograph shows the SIEA 747 
flap being raised from the lower abdomen and the SIEA pedicle entering flap tissues and 748 
bifurcating. The SIEA can be cannulated and infused with as shown in the photograph 749 
(top right) where 0.5 mL of a 1% methylene blue solution has been infused. Flaps are 750 
inset into the ventral hind limb and the donor site closed primarily with wound healing 751 
being complete by 2 weeks post-operatively (bottom left).  B) Schematic of the 752 
fractionation pilot study comparing 3 biologically equivalent fractionation regimens (n=3 753 
per cohort): 30 Gy/single fraction, 40 Gy/2 fractions or 50 Gy/3 fractions. Fractions were 754 
all delivered on consecutive days. SIEA flaps were inset into the hind limb and were 755 
irradiated 30 days post-operatively. Animals were maintained for 180 days with clinical 756 
and radiological follow-up prior to flap tissues being harvested for histological and 757 
molecular analyses. C) Representative photographs (dots represent SIEA flap margins) 758 
demonstrating the spectrum of acute toxicities observed following irradiation: i) dry 759 
desquamation, ii) patchy moist desquamation and iii) confluent wet desquamation. Acute 760 
toxicities can be quantified using the RadioTherapy Oncology Group (RTOG) acute 761 
scoring system (iv), which demonstrated that flaps irradiated with 50 Gy/3 fractions 762 
exhibited the most sustained acute toxicities. Flaps irradiated with 30 Gy and 40 Gy 763 
fractionation regimens developed acute toxicities for a shorter duration (21 days). D) 764 
Appearance of SIEA flaps at 180 days post-irradiation showing that flaps irradiated with 765 
50 Gy/3 fractions exhibit a phenotype that is characteristic of LAEs as demonstrated by 766 
the presence of significant contracture, pigmentation change (black arrow), telangiectasia 767 
(red arrow) and hair loss. E and F) Quantification of skin paddle surface area (mean ± 768 
95% CI) showed that contracture was seen in all 3 fractionation cohorts but the greatest 769 
degree of contracture was observed in the 50 Gy/3 fraction cohort. G) RTOG late adverse 770 
effect scoring demonstrated that only the 50 Gy/3 fraction cohort developed measureable 771 
LAEs that became progressively more severe over the duration of the experiment. These 772 
changes were observed both in cutaneous, subcutaneous and underlying joint tissues. H) 773 
LAEs affecting knee joint function and passive range of movement (ROM) developed 774 
late in the experiment in the 50 Gy/3 fraction cohort whereas animals with SIEA flaps 775 
irradiated with 30 and 40 Gy did not develop any LAEs in their joints. I) SOD2 776 
biochemical assay (i) demonstrating significant reductions in SOD2 activity in irradiated 777 
flaps compared to control flaps even at 180 days post-irradiation. SOD2 activities 778 
between fractionation cohorts were not significantly different however a trend was 779 
observed to suggest that the greatest reductions were observed with the largest doses per 780 
fraction. ii) Western blot for SOD2 demonstrating a similar pattern of reduction in protein 781 
expression levels in irradiated flaps compared to controls. J) i) ELISA for CTGF 782 
demonstrating significant increases in CTGF expression in irradiated flap tissues 783 
harvested at 180 days post-irradiation. The 50 Gy/3 fraction cohort exhibited the greatest 784 
increases in CTGF concentration. Western blot analyses for phosphorylated GSK-3 785 
(Ser
9
) demonstrating increases in GSK-3 phosphorylation with total radiation dose 786 
delivered (image representative of all experiments) suggesting activation of the Wnt-787 
pathway following irradiation. K-O) Histological analysis of irradiated SIEA flaps. K) 788 
Immunohistochemical staining for CTGF demonstrating a significant increase in CTGF 789 
expression in flaps irradiated with 50 Gy/3 fx compared to controls and those irradiated 790 
with 30 Gy. L) SOD2 immunohistochemistry in irradiated and non-irradiated controls. 791 
The latter group exhibited significantly greater SOD2 expression compared to all 792 
irradiated groups. M) Masson’s trichrome staining for collagen deposition in controls and 793 
irradiated flaps demonstrating a signficant increase in collagen deposition in flaps 794 
irradiated with 50 Gy/3 fx.  N) Dermal PTEN immunohistochemistry demonstrating a 795 
significant reduction in PTEN expression in all irradiated flaps. O) H&E staining for the 796 
quantification of fat necrosis within irradiated flaps demonstrating a significant increase 797 
in fat necrosis in flaps irradiated with 50 Gy/3 fx compared to controls and those 798 
irradiated with 30 Gy (p = 0.039). [*** p < 0.0001, ** p < 0.01, * p < 0.05]. 799 
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Figure 2. LAEs are characterized by vascular dysfunction, loss of endothelial perfusion and 807 
permeability and peri-vascular hypoxia. A) Parametric R2* maps of control and 808 
irradiated flaps overlaid on T2-weighted images acquired 6 months following irradiation. 809 
B) i) Absolute changes in R2* (mean  1 SEM) demonstrating that, in irradiated flaps, 810 
basal R2* was reduced significantly from 1 month onwards. Asterisks represent 811 
comparisons made with the pre-irradiation time point for each group separately. ii) 812 
Relative changes in R2* (mean  1 SEM) demonstrating that irradiated flaps exhibited 813 
greater reductions in relative R2* compared to control flaps at all post-irradiation time 814 
points. [ns = not significant, * p < 0.05, **** p < 0.0001]. C) Hoechst 33342 uptake, 815 
Evans blue leakage and pimonidazole adduct formation in control (i) and irradiated (ii) 816 
flaps (H&E and composite scan (x 10 magnification) of entire section inset with red box 817 
representing zoomed micrograph) demonstrating a significant reduction in Hoechst 818 
33342 and Evans blue fluorescence and an increase in pimonidazole adduct 819 
immunofluorescence. D) Quantification of Hoechst 33342 uptake, Evans blue leakage 820 
and pimonidazole adduct formation. Bars represent mean percentage of section exhibiting 821 
staining (SEM). Images are representative of the larger cohort (n = 3 animals with 822 
bilateral flaps). Scale bars (bottom right) represent 100 m. [*** p < 0.001, **** p < 823 
0.0001]. E, F and G) Post-radiation changes in microvascular function demonstrating 824 
reductions in Hoechst 33342 uptake (E), Evans blue fluorescence (F) and an increase in 825 
pimonidazole adduct immunofluorescence (G) (with H&E of section inset) in control and 826 
irradiated flaps with 50 Gy/3 fx. Note perivascular fibrosis around irradiated vessels 827 
(G.iii and vi; black arrow) and correlation with pimonidazole staining (G.ii and v; white 828 
arrow). Images are representative of the larger cohort. Scale bar (bottom right) is equal to 829 
20 m. 830 
831 
Fig. 3. Mitochondrial SOD2 over-expression in normal, but not tumour cells, mediates 832 
radioprotection across a range of fractionation schedules and durable SOD2 over-833 
expression can be achieved in vivo.  834 
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Fig. 3. SOD2 over-expression preserves reactive oxygen species scavenging capacity 
after RT and durable transgene expression can be achieved in vivo. A) Graph of 
SOD2 activity (mean  SEM) in rat fibroblasts (RF) at 2, 6 and 24 hours after irradiation 
with 0, 8 or 16 Gy of radiation. The graph shows a dose-dependent reduction in SOD2 
activity that occurs earlier with higher radiotherapy doses. B) Post-irradiation changes in 
SOD2 activity in RF cells over-expressing SOD2 (RF-LVSOD2) compared to vector 
(RF-LVGFP) and naïve (RF) controls demonstrating significant preservation of SOD2 
activity in the RF-LVSOD2 cell line compared to controls. C) MTT assays performed 
using endothelial cells (YPEN1) and endothelial cells over-expressing SOD2 (YPEN1 
SOD2) at 120 hours post-irradiation demonstrating significantly greater cell survival in 
the presence of SOD2 over-expression across a variety of biologically equivalent 
fractionation schedules. D) Three-dimensional spheroid assays using YPEN1 and YPEN1 
SOD2 following irradiation across a range of biologically-equivalent fractionation 
schedules demonstrating significantly greater spheroid volume preservation after RT in 
cells over-expressing SOD2. E) MTT assay (120 hours) investigating the effect of 
silencing transiently SOD2 expression using siRNA in cells over-expressing SOD2. 
Control (YPEN1) endothelial cells (ECs) and ECs over-expressing SOD2 were irradiated 
and demonstrated a survival benefit in cells over-expressing SOD2, which was mitigated 
by the addition of SOD2 siRNA but not the addition of a scrambled siRNA control. F) 
Confirmation of SOD2 knock-down using siRNA by RT-QPCR demonstrating that 
SOD2 gene expression was significantly reduced (to almost 10% of basal levels). G) i) 
Quantification of clonogenic assays (mean SF  SEM) of HeLa and HeLa-LVSOD2 
demonstrating a significant increase in SF in HeLa-LVSOD2 at 2 Gy. The trend at 4 and 
6 Gy (ii) is suggestive of improved survival in HeLa-LVSOD2. H) i) Quantification of 
clonogenic assays comparing FaDu and FaDu-LVSOD2 (mean SF  SEM). This graph 
shows a trend suggestive of greater survival in FaDu-LVSOD2 at all radiation doses (ii). 
I) i and ii) Confocal immunofluorescent microscopy of control and SOD2 over-
expressing fibroblasts (RF) using an anti-cytochrome C oxidase antibody (MTCO1) and 
anti-SOD2 primary antibody demonstrating visible over-expression of SOD2 in the 
RFSOD2 cells (ii) and co-localization of SOD2 with MTCO1. Cell lysates were collected 
and split into mitochondrial and cytosolic lysates. Biochemical SOD2 activity was found 
to be increased significantly in whole cell and mitochondrial lysates of RFSOD2 cells 
compared to RF controls but this difference did not reach statistical significance for the 
cytosolic compartment. J) Immunohistochemical staining for SOD2 protein expression in 
superficial inferior epigastric arteries of flaps infected with LVSOD2 (10
8
 TUs) (i) 
compared with sham (PBS) (ii) controls demonstrating greater protein expression within 
the vascular compartment. These increases were associated with increased SOD2 activity 
(iii) and equated to a 50% increase in basal SOD2 activity in flap tissues. SIEA flaps 
infected with LVSOD2 did not have significantly lower levels of CTGF protein 
expression (iv) but those infected with both LVSOD2 (10
8
 TUs) and LVshCTGF (10
8
 
TUs) exhibited a significant reduction in CTGF concentration (relative 40% decrease). K 
and L) The flap pedicle, containing only artery and vein, was dissected from the flaps 
(sham and 10
8
 TUs of LVSOD2) and RT-QPCR was performed using pedicle RNA (K) 
to demonstrate significant over-expression of the SOD2 gene in vascular tissues of flaps 
infected with LVSOD2. This was also associated with significantly increased SOD2 
biochemical activity (L) in flaps infected with LVSOD2. M) Immunofluorescent staining 
for GFP demonstrating vascular transgene expression at 6 months post-infection with 
LVeGFP in the SIEA (x 40 (i) and x100 (ii)), SIEV (iii) alongside a negative 
experimental control (PBS sham infection) (iv). GFP expression was also observed in the 
microvasculature as demonstrated by co-localization of GFP (green) (v and vi; x100). 
Nuclei are counter-stained with DAPI (blue). Extra-vascular GFP expression was also 
observed in the stromal compartment (adipocytes) of the flap as demonstrated by co-
localization with fatty acid binding protein 4 (FABP4) (vii (x40) and viii (x100)) at 6 
months post-infection (red square represents the area of higher magnification in vii). N) 
Q-PCR for the quantification of viral copy number in SIEA flaps at 6 months post-
infection showing that flap infection with 10
8 
TUs of LVeGFP results in an approximate 
10,000-fold increase in viral copy number compared to un-infected flap tissues. [* p < 
0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001]. 
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Fig. S2. Validation of CTGF knock down using LVshCTGF. A) SOD2 activity assay (mean  
SEM) comparing two commercially available lentiviral backbones encoding the SOD2 
gene sequence: pLV-III-SOD2-CBS and pLV-III-SOD2-ABM. Lentiviral particles were 
generated using both plasmids and used to infect RF cells to create 2 different SOD2 
over-expressing stable cell lines: RF-LVSOD2-CBS and RF-LVSOD2-ABM. Assaying 
for SOD2 activity demonstrated significantly greater SOD2 activity in RF-LVSOD2-CBS 
compared with RF-LVSOD2-ABM. B) Relative SOD2 activity, normalized to RF control 
cells demonstrating that RF-LVSOD2-CBS cells have a 4-fold increase in basal SOD2 
activity. C) Mean basal CTGF concentrations ( SEM) in absolute (i) and relative (ii) 
terms across RF controls, RF-LVshCTGF and RF-LVshCTGFscram (1x10
6
 cells). The 
data show that LVshCTGF knocks down basal CTGF levels to approximately 50% of 
control concentrations (ii). D) When CTGF expression is stimulated by the exogenous 
addition of TGF-1 (5 ng/mL) infection with LVshCTGF still maintains knock down to 
50% of control CTGF concentrations (i and ii).  E) MTT assay performed at 2 hours after 
irradiation. Graph displays mean surviving fraction (SF)  SEM. No differences were 
observed between control and SOD2 over-expressing cell lines at 2 (i) or 96 (ii) hours 
post-irradiation with 8 or 16 Gy.  
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Fig. 4. LVSOD2 and LVshCTGF therapy reduce volume loss and skin contracture 
following RT. A) Phenotypic appearance of irradiated (50 Gy/3 fractions) SIEA flaps at 
180 days following irradiation. Significant improvements in the LAE phenotype were 
observed in flaps infected with LVSOD2 and LVshCTGF either alone, or, in combination 
(i-v). Note the appearance of LAEs such as telangiectasia in adjacent tissues into which 
neither LVSOD2 nor LVshCTGF were delivered (iii red arrows). Quantification of the 
skin paddle changes (mean skin paddle surface area ± 95% CI) demonstrated significant 
differences between therapy groups (vi and vii) at 180 days post-irradiation. Specifically, 
flaps infected with LVSOD2 or LVshCTGF as single agents exhibited significantly less 
skin paddle contracture than sham (PBS) or vector control (LVscram) infected flaps. 
LVshCTGF monotherapy showed a trend towards greater skin paddle preservation 
compared to LVSOD2 alone however this did not reach statistical significance. 
Combination therapy with LVSOD2 plus LVshCTGF achieved the greatest 
improvements in skin paddle contracture with irradiated flaps losing approximately 15% 
of their pre-irradiation surface area, compared to controls that lost approximately 70%. B) 
RTOG scores for acute toxicities following irradiation demonstrating that flaps infected 
with LVSOD2 (either alone or in combination) experienced a shorter duration of acute 
toxicities that resolved sooner (i and iii), however, the maximum severity of acute 
toxicities was no different between groups. C) RTOG severity scoring for LAEs in 
irradiated flaps (I, iii, v and vii) and RTOG score component breakdown (ii, iv, vi, viii) 
showing that flaps receiving LVSOD2 monotherapy attained significantly lower RTOG 
scores for subcutaneous tissue effects (ii). Flaps infected with LVshCTGF achieved lower 
RTOG scores for cutaneous effects (iv) in the early and intermediate term but these did 
not persist to the end of the experiment. Flaps receiving dual therapy achieved sustained, 
lower severity scores for both cutaneous and subcutaneous effects (vi). Of note, no 
therapeutic group experienced a reduction in severity scores for joint-related effects 
suggesting that radioprotective effects do not leech out of the flap to its bed. D) T2-
weighted in vivo MRI of irradiated flaps (red arrows) at 180 days following the cessation 
of radiotherapy showing that flaps infected with LVSOD2 retained significantly more 
subcutaneous volume than other therapeutic groups. MRI-derived volumetric analysis 
(vi) revealed that flaps infected with LVSOD2, either alone or in combination, retained 
up to 80% of their pre-irradiation volumes, and were also seen to experience significant 
improvements in relative basal R2* and were not statistically different from un-irradiated 
flaps (vii). [*p<0.05; **p<0.01; ***p<0.001]. 
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Fig. 5. Combination therapy with LVSOD2 and LVshCTGF reduces fibrosis post-RT but the preservation of microvascular function 
is attributable to LVSOD2 only 
 
 

  
 
 Submitted Manuscript:  Confidential             template updated: February 28 2012 
 
 
Fig. 5. Combination therapy with LVSOD2 and LVshCTGF reduces fibrosis post-RT but 
the preservation of microvascular function is attributable to LVSOD2 only. A) 
Western blotting for SOD2 in flap tissues taken at 180 days after irradiation with 50 Gy/3 
fractions. These data show that the observed reductions in SOD2 expression after RT 
seen in control groups (PBS and LVscram) are mitigated by the delivery of LVSOD2. Of 
note, LVshCTGF therapy alone does not appear to impact post-irradiation changes in 
SOD2 expression. B) Masson’s trichrome staining for the quantification of fibrosis in 
flap tissues taken at 180 days after irradiation from each therapeutic group (i-vi). Photos 
are representative of the larger cohort and whole sections are presented inset (top left). 
Reductions in collagen deposition (green) were observed in both flaps infected with 
LVSOD2 and LVshCTGF as monotherapies (iii and iv). Combination therapy with 
LVSOD2 plus LVshCTGF yielded further reductions in collagen deposition compared to 
controls (i and vi). C) i) Quantification of Masson’s trichrome staining showing 
significant differences in collagen deposition between groups. Specifically, flaps infected 
with LVSOD2 and LVshCTGF as monotherapies exhibited significantly less fibrosis than 
controls (p<0.01) whereas flaps infected with both vectors exhibited further significant 
reductions in collagen deposition (p<0.05). Correlative RT-QPCR for Col1a2 gene 
expression in flap tissues at 180 days post-irradiation demonstrated muting of expression 
in flaps infected with LVSOD2 (either alone or in combination). LVshCTGF 
monotherapy resulted in greater Col1a2 expression compared to sham (PBS) and vector 
(LVscram) controls (p<0.05) but this did not result in greater collagen deposition (figure 
6.b.iv). D) Immunofluorescent imaging of functional vasculature (Hoechst 33342 
(H33342) and Evans blue (EB)) and hypoxia (pimonidazole (P)) in flap tissues taken at 
180 days following the end of radiotherapy (i-vi). Images are presented as merged 
composites (whole section upper panel and x40 middle panel) and split channels (lower 
panel). These data show differences in H33342, EB and P across therapeutic groups. 
Specifically, flaps infected with LVSOD2 (either alone or in combination) have 
preservation of H33342 (viable endothelium) and EB (vascular permeability) and a 
commensurate reduction in P (hypoxia) staining (iii and v). E) Thresholded imaging 
analysis of immunofluorescent staining for H33342, EB and P demonstrating statistically 
significant changes. Flaps infected with LVSOD2 (either alone or in combination) 
showed significant improvements in perfused vasculature (H33342) (i), vascular 
permeability (EB) (ii) and a reduction in hypoxia (P) (iii). Flaps infected with 
LVshCTGF showed reductions in perfused vasculature (H33342) (i) and greater hypoxia 
(P) compared to flaps receiving LVSOD2. However, LVshCTGF flaps showed modest, 
but significant, improvements in vascular permeability (EB) (ii) compared to sham (PBS) 
and vector (LVscram) controls. However, these improvements remained significantly less 
than those seen with LVSOD2 therapy. F) Multiplexed immunofluorescent staining for 
GFP and RFP expression at 180 days post-irradiation in flaps that have been infected 
with LVSOD2-RFP and LVshCTGF-GFP (10
8
 TUs each) and irradiated with 50 Gy/3 
fractions. Images are shown alongside negative controls at x20 (i) and x40 (iii) 
magnification Images show co-localization of GFP and RFP expression (ii and iv), 
particularly within vessel walls (L = lumen) but also in the extra-vascular compartment. 
Cells demonstrating GFP expression alone (white arrows) or RFP expression alone (red 
arrows) are also observed. [* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001]. 
 
 Fig. 6. SOD2 over-expression in normal tissues does not compromise the cytotoxic efficacy 
of RT 
 
Fig. 6. SOD2 over-expression in normal tissues does not compromise the cytotoxic efficacy 
of RT. A) Western blotting for SOD2 to demonstrate that despite SOD2 over-expression 
(double band) in stable, producer (LVSOD2-HeLa) cells SOD2 over-expression is not 
seen in naïve target cells following inoculation with media taken from producer cells. B) 
Schematic of the in vivo tumour recurrence model using MatBIII cells (rodent breast 
adenocarcinoma). Animals underwent SIEA flap surgery as described previously, with 
the delivery of LVSOD2, LVeGFP or sham (PBS). One month later MatBIII cells were 
engrafted into the flap and established tumours (photo bottom right of panel showing 
established MatBIII tumour (red arrow) in an SIEA flap (paddle outline dashed white)) 
were irradiated with 20 Gy/5 fractions (n= 5 animals per group). C) Tumour volume 
growth for MatBIII tumours in flaps infected with LVSOD2, LVeGP or sham (PBS) 
demonstrating significant differences in tumour volume growth. Following irradiation 
with 20 Gy/5 fractions tumours growing in LVSOD2-infected flaps exhibited 
significantly slower tumour growth compared to those growing in flaps infected with 
control vectors. D) Individual growth curves for tumours growing in: sham (PBS) 
infected and un-irradiated (i), sham (PBS) infected and irradiated (20Gy/5 fractions) (ii), 
LVSOD-infected and irradiated (20 Gy/5 fractions) (iii) and LVeGFP-infected and 
irradiated (20 Gy/5 fractions) (iv). These data show that 4 out of 5 tumours irradiated in 
LVSOD2-infected flaps achieved remission whereas only 1 out of 5 tumours in each 
control group (sham (PBS) and vector (LVeGFP)) achieved remission. E) Kaplan-Meier 
plot of survival to humane end-point for animals with MatBIII tumours grown in sham 
(PBS), LVSOD2 or LVeGFP flaps showing significant differences in survival. Animals 
with LVSOD2-infected flaps did not achieve median survival whereas animals with 
control (sham (PBS) or vector (LVeGFP)) flaps had significantly shorter median survival 
(PBS: 27 days, LVeGFP: 25 days).  
 
Supplementary Materials: 
Supplementary methods 
Immunohistochemistry 
In vivo specimens were fixed in formalin for 24 hours after harvest, embedded and 
mounted. Sections for immunohistochemical analysis were cut at 3 m thickness. Sections were 
de-waxed, washed and antigen retrieval performed (CTGF: 97C for 20 min in pH 6 citrate 
buffer (Dako S2031, Ely, UK); SOD2: pressure cook for 2 min in pH 6 citrate buffer (Dako 
S2031); PTEN: 97C for 20 min in pH 6 citrate buffer (Dako S2031)). Sections were rinsed in 
wash buffer (Dako S3006) and endogenous peroxidases blocked (Dako S2023). Sections were 
incubated with primary antibody (CTGF (1:500; Abcam, Cambridge, UK), SOD2 (1:400; 
Abcam, Cambridge, UK) and PTEN (1:100; Cell Signalling Technologies, Leiden, Denmark)) in 
antibody diluent (Dako S2022) for 1 hour at room temperature. Sections were washed and Dako 
Envision HRP Polymer (K4011) applied for 30 minutes at room temperature. Immunostaining 
was then visualized using liquid DAB (3,3’-diaminobenzidine) (Dako) substrate for 5 minutes 
before sections were washed, counterstained with haematoxylin (CellPath, Newton, Wales) and 
mounted. For Masson’s trichrome staining, Weigerts haematoxylin A and B (TCS Bioscience, 
Buckingham, UK) were mixed in a 1:1 ratio and applied to sections for 5 minutes. Sections were 
washed and stained using the Masson’s Trichrome light green kit (TCS Bioscience). For CTGF, 
SOD2 and PTEN immunohistochemical staining, counts were performed in three x 20 fields in 3 
non-consecutive sections of tissue per in vivo sample. For CTGF, SOD2 and PTEN, positivity 
was defined by the presence of membranous or cytoplasmic staining. Fibrosis was quantified by  
as the percentage of the whole section exhibiting fibrotic change using post-hoc imaging 
software (Image J, NIH, Bethesda, USA).  
 
Immunofluorescence 
Sections were de-waxed, rehydrated, permeabilized in 0.2% Triton detergent (Sigma-
Aldrich, Gillingham, UK) and blocked with IFF for 1 hour. Sections were then incubated with 
primary antibody (anti-eGFP (rabbit polycloncal 1:100, Abcam, Cambridge UK) at 4C 
overnight. Co-staining was performed using anti-CD31 (mouse polyclonal 1:100, Novus 
Biologicals, Cambridge, UK) and anti-FABP4 (fatty acid binding protein 4) (mouse polyclonal 
1:200, R and D Systems, Abingdon, UK) with anti-eGFP. The following day, sections were 
washed in PBS and incubated with a goat anti-rabbit 488 (eGFP) and/or chicken anti-mouse 555 
(CD31 and FABP4) FITC-conjugated secondary antibody (1:1000 in IFF) (Life Technologies, 
Paisley, UK) for 1 hour at room temperature and then washed in PBS with 4’,6-diamidino-2-
phenylindole (DAPI; 1:50,000; Sigma-Aldrich, Gillingham, UK). Sections were then rinsed and 
fixed in paraformaldehyde (4%) for 15 minutes. Confocal images were captured on a Leica 
Microsystems TCS-SP2 confocal (Leica Microsystems, Milton Keynes, UK). Controls sections 
included experimental controls (SIEA flaps that had not been infected with LVeGFP) and 
staining controls (LVeGFP-infected flaps incubated with either primary or secondary antibody 
only). Three non-consecutive sections from each sample were examined by fluorescence 
microscopy.  
 
Multi-plexed immunofluorescent imaging 
Frozen sections were fixed on the slide with 4% PFA, subjected to antigen retrieval in 
Citrate buffer (10mM Sodium Citrate Buffer, 0.05% Tween 20, pH 6.0) and blocked with 
rabbit/mouse serum for 10 mins before application of anti GFP antibody (Abcam, Cambridge, 
UK) at a concentration of 1in100, at room temperature for 30 minutes. Slides were washed 3x in 
TBST before addition of anti-rabbit/mouse HRP conjugated secondary antibody (Perkin Elmer) 
for 10 minutes. Slides were washed again 3x, before addition of Opal HRP substrate (Perkin 
Elmer) for 20 minutes. Upon completion of the first staining, antibodies were stripped by 2 
minutes antigen retrieval in Citrate buffer and the whole staining process repeated for RFP 
antibody (Abcam, Cambridge, UK) (1 in 100). Stained sections were imaged using a Vectra 3.0 
multispectral microscope (Perkin Elmer). 
 
Cell lines 
Immortalized rat fibroblasts (RFs) (kind gift from Prof Tony Ng, King’s College, 
London), HeLa (human uterine cervical adenocarcinoma) and FaDu (human hypopharyngeal 
squamous cell carcinoma) cells were maintained in DMEM supplemented with 10% foetal calf 
serum (BD Biosciences, Oxford, UK), 2 mM l-arginine (CSSD, ICR) and 1% 
penicillin/streptomycin (CSSD, ICR). Rat MatB IIIbreast adenocarcinoma cells (ATCC, 
Teddington, UK) were maintained in McCoy’s 5A (modified) medium (Gibco®, Life 
Technologies Inc., Paisley, UK) supplemented with 10% FCS, 2 mM l-arginine and 1% 
penicillin/streptomycin. Cells were cultured in a humidified incubator at 37C (95% air, 5% 
CO2). Cells were routinely tested for the presence of mycoplasma infection.  
 
Generation of stable cell lines 
Target cells were plated at between 1-5 x 10
5
 cells per 6 cm or 10 cm tissue culture dish 
24 hours prior to infection with lentivirus. The following day, medium was aspirated from the 
target cells and a lentiviral inoculum (1-5 mL) was added to the cells with fresh DMEM (+10% 
DMEM) and polybrene (1 g/mL). The following day the inoculum was aspirated and replaced 
with fresh medium. After 72 hours, puromycin at a concentration ranging from 0.5-20 g/mL 
was added to the medium to select for infected cells. Cells were propagated, thereafter, in 
medium with puromycin. 
 
Protein quantification 
Protein concentration of the lysates was determined using the Bicinchoninic Acid (BCA) 
Protein Assay Reagent (Pierce, Rockford, IL). Reagents and samples were combined as per the 
manufacturers instructions and absorbances read at 570 nm (SpectraMax, Sunnyvale, CA, USA). 
Protein concentrations were derived from an albumin standard as per the manufacturer’s 
protocol.  
 
Western blotting 
Thirty micrograms of lysate was mixed with 7.5 L Laemmeli buffer (Sigma-Aldrich, 
Gillingham, UK) and made up to a total volume of 25 L with sterile water. Samples were then 
heated at 95C for 5 minutes and loaded onto SDS polyacrylamide gels (10% Bis-Tris) (Life 
Technologies Inc., Paisley, UK) running in MOPS buffer (Life Technologies Inc., Paisley, UK). 
Electrophoresis was performed at 100 volts (V) at room temperature. Proteins were transferred 
onto a polyvinylidenedifluoride (PVDF) Hybond-P membrane (0.45 m) (Amersham, Arlington 
Heights, IL) using a wet transfer protocol in transfer buffer (192 mM glycine, 25 mM Tris and 
200 mM methanol (CSSD, ICR) at pH 8.3). Following this, membranes were rinsed in Tris-
buffered saline containing 0.1% TWEEN-20 (Sigma-Aldrich, Gillingham, UK) (TBS-TWEEN) 
and then blocked in a 5% milk solution (5 g powdered milk in 100 mL TBS-TWEEN).   
 
Immunodetections were performed using a variety of primary antibodies incubated 
overnight with membranes in a 5% milk solution. The following day, membranes were washed, 
incubated with the appropriate secondary antibody (sheep anti-mouse IgG or donkey anti-rabbit 
rabbit IgG (1:1000 (ECL™, GE Healthcare Ltd., Bedford, UK) (in 5% milk solution) for 1 hour 
at room temperature and washed once more. Detections were carried out using the Immobilon 
Western chemoluminescent horseradish peroxidase (HRP) substrate (Millipore, Watford, UK). 
Membranes were exposed to photographic films (Fujifilm Global, Tokyo, Japan) and developed. 
Equal loading was assessed using β-actin or -tubulin (Sigma) mouse monoclonal primary 
antibodies.  
 
SOD2 activity assay 
Assays were performed using a high throughput SOD2 assay (Sigma Aldrich, 
Gillingham, UK) as per the manufacturer’s protocol. The assay relies upon the competitive 
inhibition of reactive oxygen species (ROS), generated in the reaction mix, by endogenous 
SOD2 to effect a colorimetric change. Formation. The assay was performed using 20 L of in 
vitro or in vivo samples (0.5 g/L) per well of a 96-well plate. Samples were mixed with 200 
L of a Wst-working solution and 20 L of xanthine oxidase (XO) was added. Standard wells 
were also set up with the omission of either the sample solution, enzyme working solution or 
both of these. Plates were incubated at 37C for 20 minutes and absorbance was then read at 450 
nm using a spectrophotometer. SOD2 activity was calculated as the “% inhibition”, which 
represents SOD2 activity relative to the standard wells.  
 
SOD2 siRNA transient knock down 
SiRNA knockdown against human SOD2 was performed using Dharmacon ON-
TARGETplus SOD2 siRNA and appropriate ON-TARGETplus SMARTPool controls 
(Dharmacon, GE Healthcare, UK) in accordance with the manufacturer’s protocols.  In brief, 1 x 
10
5 
 YPEN1-SOD2 overexpressing cells were plated onto six well culture plates (NUNC, 
ThermoFisher Scientific, UK), in complete DMEM supplemented with 10% FCS (The Institute 
of Cancer Research, London, UK). The next day, 10μl of 5μM SiRNA was diluted with 190μl 
serum-free Optimem (Glibco, ThermoFisher Scientific, UK), and incubated with 2μl of 
Lipofectamine RNAiMAX transfection reagent (Thermo Fisher Scientific, UK) diluted in 198μl 
Optimem for 20 minutes at room temperature.  This was added to 1600μl of complete DMEM 
10% FCS, mixed adequately and used to replace the media on the plates.  24 hours later the 
media was replaced with 2ml of complete DMEM 10% FCS and the cells used for experiments. 
 
CTGF ELISA 
A commercially-available ELISA for CTGF was used (Peprotech Ltd., London, UK) and 
assays were performed as per the manufacturer’s instructions. In brief, 100 L of a capture 
antibody solution (1 g/mL) was plated per well of a 96-well plate (R and D Systems, Abingdon, 
UK) and left to incubate overnight at room temperature. The following day, the capture antibody 
was discarded and the plate washed and blocked with a sterile-filtered, blocking solution (PBS + 
1% bovine serum albumin (Sigma-Aldrich, Gillingham, UK)) for 1 hour at room temperature 
and washed again. Samples were loaded in triplicate on the plate alongside a CTGF standard 
(range: 62.5 – 4,000 pg/mL) and left to incubate at room temperature for 2 hours. The plate was 
then washed and a solution of biotinylated-detection antibody (0.5 g/mL, 100 L/well) added to 
each well and left to incubate for 2 hours. The plate was washed once more and 100 L of an 
avidin solution (6 L of a stock solution diluted in 12 mL of diluent (PBS + 0.1% BSA + 0.05% 
TWEEN)) added to each well and left to incubate for half an hour. One hundred microlitres of 
ABTS (2,2′-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) liquid substrate (Sigma-Aldrich, 
Gillingham, UK) was added to each well and absorbance was read (at 450 nm with a wavelength 
correction set to 650 nm) at 5 minute-intervals for 45 minutes. Data analysis was performed as 
per the manufacturer’s instructions using readings obtained from the CTGF standards to 
extrapolate CTGF concentrations within samples.  
 
3-(4,5-dimethylthiazol-2-y)-2,5-diphenyltetrazolium bromide (MTT) assay 
5 x 10
4
 cells were plated per well of a 96-well plate and allowed to attach prior to 
irradiation. At the experimental end points (24 and 96 hours), 20 L of MTT (Sigma-Aldrich, 
Gillingham, UK) was added to each well and the plate incubated for 4 hours. At this point, the 
medium was aspirated and 200 L of 100% DMSO solution was added to each well. Plates were 
placed on a rocker to facilitate dissolution of MTT crystals and 1 hour later absorbances were 
read at 550 nm using a spectrophotometer.  
 
Clonogenic assay 
To investigate longer-term survival following irradiation, cells were plated at a range of 
seeding densities in separate wells of a 6-well plate. The following day, cells were irradiated 
with 0, 2, 4 or 6 Gy and incubated at 37C for 10 to 14 days thereafter. At this time, the medium 
was discarded and colonies fixed with a crystal violet solution (0.2% crystal violet, 0.7% 
ethanol). Clonogenic assays were quantified digitally using CellProfiler 2.0 (Broad Institute, 
Cambridge MA, USA). Briefly images were converted to greyscale, contrast enhanced to make 
colonies more distinct from background and inverted for processing with CellProfiler. 
Quantification measured the average plating efficiency from duplicate wells per experiment, with 
a minimum of three independent experiments per condition. Surviving fractions were calculated 
from the control plating efficiencies for independent repeats. 
 
Spheroid assay 
5x10^4 cells per well were plated in U-bottom low attachment plates (Corning, NY, 
USA). 96 h after plating spheroids were irradiated. Radiation doses used were either 5 Gy or 8 
Gy radiation in a single fraction on day 1, or three 2.4 and 4.15 Gy fractions on consecutive days 
1-3. Media was changed three times per week. Spheroids were imaged and automated area 
quantification performed at day 12 using a Celigo S high throughput micro-well image cytometer 
(Nexcelom, MA, USA). Values were adjusted relative to the average area of the control spheroid 
group. A minimum of 11 spheroid measurements per condition were quantified across two 
biologically independent repeats. 
 
Polymerase chain reaction (PCR) 
RNA and genomic DNA (gDNA) were extracted from 0.1 g of flap tissue using 
commercially-available nucleic acid extraction kits (Qiagen RNeasy kit and DNeasy Blood and 
Tissue kit, Qiagen, Hilden, Germany). All extractions were performed as per the manufacturer’s 
instructions. cDNA synthesis was performed using the RT
2
 First Strand cDNA synthesis kit 
(Sabiosciences, Crawley, UK). In brief, 500 ng of extracted RNA was mixed with 2 L buffer 
GE and made up to a volume of 10 L using RNase-free water. This was incubated at 42C for 
15 minutes to eliminate gDNA and then placed on ice for 1 minute. A reverse transcription mix 
was made using: 4 L 5 x Buffer BC2, 1 L control P2, 2 L RE3 reverse transcriptase mix and 
3 L RNase-free water (total volume = 10 L). The genomic elimination mix (10 L) was mixed 
with the reverse-transcription mix and pipetted up and down. This was then incubated at 42C 
for 15 minutes to allow for reverse transcription. The reaction was stopped by incubating the mix 
at 95C for 5 minutes and 91 L of RNase-free water added.  
 
PCR for CTGF, Col1a2, Col3a1 and SOD2 
RT-QPCR using primers for CTGF, Col1a2, Col3a1, SOD2 and -actin (QuantiTect 
Primer Assays, Qiagen, Hilden, Germany) was performed. Reactions were performed using 50 
ng of cDNA mixed with 2 L primer solution (20 M) and made up to a volume of 10 L with 
RNase-free water.  Reactions were amplified using SYBR Green and the StepOne™ Q-PCR 
system (Applied Biosciences, Life Technologies, Paisley, UK). Amplification was performed 
under the following cycling conditions: 95C 10 minutes (1 cycle) (denaturing), 95C 10 
s58C 10 s72C 10 s (40 cycles) (quantification), 40C 20 s (1 cycle) (cooling). Changes in 
expression were calculated using the ddCT method and reported normalized to housekeeping 
genes (-actin).  
 
PCR for viral DNA 
Quantitative PCR (Q-PCR) using primers targeted against the 5’ end of the gag gene was 
performed to quantify the presence of viral DNA in infected flap tissues. The primer sequences 
were obtained from Capital Biosciences (Rockville, USA). 100 ng of gDNA was mixed with 0.5 
L of forward (FW) and reverse (RV) primers (gag: FW: 5'-
GGAGCTAGAACGATTCGCAGTTA-3'; RV: 5'-GGTTGTAGCTGTCCCAGTATTTG-3';), 2 
L SYBR Green mastermix and made up to a volume of 20 L DNase/RNase-free water. 
Commercially-available primers for rat -actin (QuantiTect Primer Assays, Qiagen, Hilden, 
Germany) were also used to standardize quantification to a housekeeping gene. PCR 
amplification was performed under the following cycling conditions: 95C for 10 minutes (1 
cycle) (denaturing), 95C 10 s60C 10 s72C 25 s (45 cycles) (quantification), 95C65C 
1 minute95C (1 cycle) (melting), 40C 30 s (1 cycle) (cooling). Gene copy number was 
calculated using the ddCT method using -actin as a housekeeping gene. 
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